Related references
Note: Only part of the references are listed.Genomic landscape of hyperleukocytic acute myeloid leukemia
Laetitia Largeaud et al.
BLOOD CANCER JOURNAL (2022)
Poor outcome of pediatric patients with acute myeloid leukemia harboring high FLT3/ITD allelic ratios
Kun-Yin Qiu et al.
NATURE COMMUNICATIONS (2022)
Hyperleukocytosis predicts inferior clinical outcome in pediatric acute myeloid leukemia
Lu-Hong Xu et al.
HEMATOLOGY (2020)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Sorafenib inhibits therapeutic induction of necroptosis in acute leukemia cells
Friederike Feldmann et al.
Oncotarget (2017)
Exchange Transfusion and Leukapheresis in Pediatric Patients with AML With High Risk of Early Death by Bleeding and Leukostasis
Ursula Creutzig et al.
PEDIATRIC BLOOD & CANCER (2016)
Continuous molecular remission and regression of side effects after discontinuation of salvage therapy with sorafenib and donor lymphocyte infusions in a young patient with relapsed AML
Jana Ernst et al.
ANNALS OF HEMATOLOGY (2016)
The Adverse Effects of Sorafenib in Patients with Advanced Cancers
Ye Li et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2015)
Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation
Fariba Fouladi et al.
LEUKEMIA & LYMPHOMA (2015)
Sorafenib Treatment Following Hematopoietic Stem Cell Transplant in Pediatric FLT3/ITD Acute Myeloid Leukemia
Katherine Tarlock et al.
PEDIATRIC BLOOD & CANCER (2015)
Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: A systematic review and meta-analysis
Sapna Oberoi et al.
LEUKEMIA RESEARCH (2014)
Sorafenib As Monotherapy or in Association With Cytarabine and Clofarabine for the Treatment of Relapsed/Refractory FLT3 ITD-Positive Advanced Acute Myeloid Leukemia
Giulia Fontanelli et al.
Clinical Lymphoma Myeloma & Leukemia (2013)
Hyperleukocytosis: Emergency Management
Richa Jain et al.
INDIAN JOURNAL OF PEDIATRICS (2013)
A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report
Brigitte C. Widemann et al.
CLINICAL CANCER RESEARCH (2012)
Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children's Oncology Group
Lillian Sung et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses
S. K. Metzelder et al.
LEUKEMIA (2012)
Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia
Hiroto Inaba et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A review of tumour lysis syndrome with targeted therapies and the role of rasburicase
P. Bose et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2011)
Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus
Mitchell S. Cairo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias
K. W. Pratz et al.
LEUKEMIA (2010)
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study
Michael Crump et al.
LEUKEMIA & LYMPHOMA (2010)
Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation
Stephan Metzelder et al.
BLOOD (2009)
Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient
Wu-Shiung Huang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review
Bertrand Coiffier et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Mutant FLT3:: A direct target of sorafenib in acute myelogenous leukemia
Weiguo Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Antitumor activity of sorafenib in FLT3-driven leukemic cells
D. Auclair et al.
LEUKEMIA (2007)
Clinical implications of FLT3 mutations in pediatric AML
Soheil Meshinchi et al.
BLOOD (2006)
Mutant FLT3 signaling contributes to a block in myeloid differentiation
R Zheng et al.
LEUKEMIA & LYMPHOMA (2005)
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
RM Stone et al.
BLOOD (2005)
Tumour lysis syndrome: new therapeutic strategies and classification
MS Cairo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: Analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98
U Creutzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation - On behalf of the Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH)
FB Taylor et al.
THROMBOSIS AND HAEMOSTASIS (2001)
Share Paper
